SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · MDT

Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Medtronic plc · Filed · SEC Form 8-K, Item 2.02

Medtronic plc company page Original on SEC.gov ↗

Revenue $9.756 billion +13.7% vs a year ago
EPS $1.14 +41.4% vs a year ago
Guidance raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue increased 13.7% year on year to $9.756 billion, and EPS climbed 41.4% to $1.14. Growth in both sales and earnings is the combination investors usually look for first. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$9.756 billion +13.7% vs a year ago

…Medtronic reported Q1 worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis.…
EPS

$1.14 +41.4% vs a year ago

…t income and diluted earnings per share (EPS) were $1.470 billion and $1.14, respectively, representing increases of 41.4% and 40.7%, respectivel…
Guidance

Guidance raised

…reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.